TScan Therapeutics, Inc. TCRX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 2.15% | 106.65% | 266.65% | -10.03% | -42.94% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.15% | 106.65% | 266.65% | -10.03% | -42.94% |
| Cost of Revenue | -19.15% | -6.78% | 4.84% | 22.97% | 21.84% |
| Gross Profit | 20.48% | 11.43% | 2.21% | -26.36% | -31.17% |
| SG&A Expenses | -8.87% | -2.09% | 4.30% | 18.29% | 23.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.90% | -5.75% | 4.72% | 21.94% | 22.14% |
| Operating Income | 17.81% | 9.30% | 0.75% | -24.44% | -29.25% |
| Income Before Tax | 13.94% | 5.46% | -1.78% | -28.12% | -30.99% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 13.94% | 5.46% | -1.78% | -28.12% | -30.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.94% | 5.46% | -1.78% | -28.12% | -30.99% |
| EBIT | 17.81% | 9.30% | 0.75% | -24.44% | -29.25% |
| EBITDA | 18.04% | 9.07% | -0.18% | -27.03% | -32.32% |
| EPS Basic | 19.99% | 9.73% | 5.49% | -14.51% | -15.53% |
| Normalized Basic EPS | 20.81% | 10.47% | 6.20% | -13.62% | -14.62% |
| EPS Diluted | 19.99% | 9.73% | 5.49% | -14.51% | -15.53% |
| Normalized Diluted EPS | 20.81% | 10.47% | 6.20% | -13.62% | -14.62% |
| Average Basic Shares Outstanding | 8.17% | 5.03% | 7.69% | 12.20% | 13.64% |
| Average Diluted Shares Outstanding | 8.17% | 5.03% | 7.69% | 12.20% | 13.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |